Syntopix is a specialised research and development business, focusing on the discovery of topical antimicrobials for healthcare and pharmaceutical applications through the repositioning of known chemical entities that have a history of use in humans.
We seek to identify compounds and develop products that treat dermatological conditions, principally acne and topical staphylococcal infections, including those due to MRSA.
Our world class antimicrobial expertise is now also being successfully applied to other areas as we develop collaborative relationships with major healthcare companies.
23/08/2010 07:00
AGREEMENT WITH GLOBAL CONSUMER PRODUCTS COMPANY
Syntopix signs an exclusive agreement with a world leading health and personal care brands company.
22/06/2010 07:00
Syntopix welcomes a new board member with Mike Townend joining as Non-executive Director
22/04/2009 13:13
03/02/2010 07:00
Syntopix announces a Directorate change with Tom Bannatyne joining as Chairman.
12/11/2009 07:00
Syntopix announces positive results for its lead dermatological compound SYN0126